Weight loss: EnteroMedics shares tank after device "fails" study

February 11, 2013 by MassDevice staff

Weight loss devices maker EnteroMedics loses half of its Wall Street value after its VBloc vagal blocking therapy system fails to meet endpoints in a pivotal trial.

EnteroMedics' Maestro VBloc system

Wall Street fled in droves after weight-loss devices maker EnteroMedics (NSDQ:ETRM) announced that its Maestro vagal blocking system failed to meet endpoints in a pivotal study, but the mass exodus isn't discouraging the company from moving forward with a bid for FDA approval.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.